About Us
| Founded: | 2022 | Updated 2026 |
| Framework: | Five-Layer Systems Oncology Model |
| Evidence Method: | CEBM-based 4-Tier Grading |
| Network: | One Day Media (OneDayMD.com, AestheticsAdvisor.com) |
| Audience: | Patients, Caregivers, Integrative Oncologists, Researchers |
| Position: | Metabolic oncology is a modulation layer — not a replacement for standard care |
About Cancer Companion Guide
We help you think like an oncologist — without being one.
| Protocol Directory | Protocols & Guides |
What Is SmartCancer.org?
Cancer is not one pathway. It is a systems-based category of diseases — each tumor shaped by its unique bioenergetic profile, its host's metabolic state, the immunological terrain it exploits, and the therapeutic pressures it adapts to over time.
SmartCancer.org — the Cancer Companion Guide — is an independent intelligence platform dedicated to systems-based metabolic oncology analysis. We integrate tumor biology, host metabolism, immune dynamics, and therapeutic modeling into one coherent, evidence-graded framework. We are a network of doctors, researchers, and medical writers. We do not sell hope. We build models.
We operate as part of the One Day Media Network — a publishing group spanning OneDayMD.com, cancer.aestheticsadvisor.com, and AestheticsAdvisor.com — dedicated to evidence-graded medical publishing across Southeast Asia and globally.
Our Mission
To provide rigorous, evidence-graded analysis of metabolic and repurposed oncology strategies — without hype, absolutism, or dogma. We operate at the intersection of five disciplines:
| Discipline | What We Analyze |
|---|---|
| Tumor Bioenergetics | Glycolysis preference, OXPHOS dependency, glutamine and lipid metabolism, metabolic plasticity |
| Host Metabolic Health | Insulin signaling, systemic inflammation, circadian biology, body composition, mitochondrial fitness |
| Immunometabolic Competition | Nutrient competition in the tumor microenvironment, T-cell exhaustion, checkpoint biology |
| Therapy–Metabolism Interaction | How chemotherapy, radiation, and targeted agents reshape tumor metabolic behavior |
| Risk–Benefit Transparency | Clear separation of evidence tiers, known harms, contraindications, and clinical readiness |
Why We Exist: The Information Gap in Oncology
Oncology research is fragmented by design. Patients navigating a diagnosis encounter a landscape full of contradictions — and conventional oncology, as practiced, often treats metabolism, immunotherapy, lifestyle, and pharmacology as separate silos.
| What Patients Currently Face | What Conventional Oncology Often Separates | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| ✓ SmartCancer.org integrates all of these — systematically and transparently. | |||||||||
The Five-Layer Systems Oncology Framework™
SmartCancer.org's proprietary model for evaluating any cancer intervention, protocol, or clinical claim.
Our Five-Layer Systems Model was developed to address a core failure of reductionist oncology: treating cancer as a single-target problem. No single pathway, drug, or intervention acts in isolation. Every tumor exists within a dynamic biological system — and our framework maps that system across five interdependent layers.
How the tumor generates energy — and how that shapes vulnerability. Covers glycolysis (Warburg Effect), oxidative phosphorylation (OXPHOS) switching, glutamine dependency, lipid synthesis pathways, and metabolic plasticity under therapeutic pressure. The Warburg Effect — preferential glucose fermentation even in oxygen-rich environments — remains central to metabolic targeting strategies.
The metabolic state of the patient — not just the tumor. Covers insulin resistance and hyperinsulinemia (major tumor growth promoters), systemic inflammation markers, circadian rhythm disruption, body composition (sarcopenia, adiposity), and mitochondrial health of normal host tissues. The metabolic terrain determines how tumors grow, resist treatment, and respond to modulation.
The local ecosystem surrounding the tumor — a critical determinant of therapy response. Covers hypoxia gradients, lactate signaling and acidosis, stromal cell interaction (cancer-associated fibroblasts), immune suppression mechanics within the TME, and extracellular matrix remodeling. Many repurposed drugs operate primarily at the TME level rather than directly on tumor cells.
The metabolic fitness of the immune system — often the decisive factor in cancer outcomes. Covers T-cell mitochondrial function, nutrient competition between tumor and immune cells in the TME, checkpoint inhibitor biology (PD-1/PD-L1, CTLA-4), NK cell metabolic requirements, and the interaction between metabolic strategies (ketogenic diet, fasting, metformin) and immune response quality.
How standard-of-care treatments alter the tumor's metabolic landscape — and what this means for combination strategies. Covers chemotherapy ROS load and mitochondrial impact, radiation-induced metabolic reprogramming, targeted therapy metabolic escape mechanisms, and the science of combining metabolic agents with standard care to prevent resistance — the Press-Pulse strategy (Seyfried model).
Evidence Grading System
Based on CEBM (Centre for Evidence-Based Medicine) principles, adapted for metabolic oncology.
Every intervention, supplement, drug, or strategy analyzed on SmartCancer.org receives a structured four-tier evidence classification. This prevents the single most common error in cancer information: treating all studies as equal.
| Tier | Classification | Evidence Sources | Clinical Relevance |
|---|---|---|---|
| TIER 1 | Established Clinical Evidence | RCTs, systematic reviews, meta-analyses, Phase III/IV trials | Supports clinical discussion with oncologist |
| TIER 2 | Early Human Data | Phase I/II trials, prospective cohorts, case series (>10 patients) | Emerging signal — warrants monitoring |
| TIER 3 | Preclinical Evidence | Animal models, in vitro studies, xenograft experiments | Mechanistic basis — not yet clinically translatable |
| TIER 4 | Mechanistic / Hypothesis | Theoretical frameworks, single case reports, mechanistic reasoning | Hypothesis generation only — high uncertainty |
What Makes SmartCancer.org Different
| What We Are NOT | What We ARE |
|---|---|
| ✗ Alternative medicine platform | ✓ Systems oncology intelligence platform |
| ✗ Anti-oncology or anti-treatment | ✓ Pro-integration, supports oncology supervision |
| ✗ Miracle-cure promoter | ✓ Evidence-tiered with explicit uncertainty ratings |
| ✗ Social media anecdote aggregator | ✓ Structured research analysis with CEBM grading |
| ✗ One-size-fits-all protocol advocate | ✓ Stage-specific, metabolic-state-specific modeling |
| ✗ Dogmatic about any single framework | ✓ Transparent about evidence limits and conflicts |
Topics We Analyze — Evidence Tier Reference
All content on SmartCancer.org is structured around rigorous topic analysis. Below is a summary of current coverage areas with their primary evidence tier signal:
| Topic | Lead Evidence Tier | Key Coverage |
|---|---|---|
| Metformin in Oncology | TIER 2 | AMPK activation, mTOR inhibition, insulin lowering, POLG mechanism |
| Ketogenic Diet in Cancer | TIER 2 | Glucose restriction, ketone metabolism, GBM and brain tumor evidence |
| GLP-1 Drugs & Cancer Biology | TIER 2 | Semaglutide obesity-cancer link, insulin sensitization, colorectal data |
| Fenbendazole in Cancer | TIER 3 | Microtubule disruption, p53 pathway, glucose transporter inhibition, 700+ case analysis |
| Ivermectin in Oncology | TIER 3 | PAK1 inhibition, Wnt signaling, cancer stem cell targeting, chloride channel data |
| Mebendazole in Cancer | TIER 2 | Phase I glioblastoma data, VEGF inhibition, colon and lung cancer preclinical |
| Immunotherapy–Metabolism Interaction | TIER 1 | Pembrolizumab + metabolic co-intervention, T-cell metabolic fitness, TME dynamics |
| Cachexia & Mitochondrial Decline | TIER 2 | Muscle wasting mechanisms, mitochondrial biogenesis, therapeutic targets |
| Circadian Biology in Tumor Control | TIER 2 | Chronotherapy, melatonin oncology, circadian clock gene expression in tumors |
| Resistance Adaptation Modeling | TIER 3 | TUBB3, pSTAT3, P-gp efflux, metabolic escape under therapeutic pressure |
Our Editorial Network & E-E-A-T Credentials
SmartCancer.org operates under the One Day Media Network, a medical publishing group founded in 2015 with primary audiences in Malaysia, Singapore, Australia, and the United States. Our content is produced by a network of physicians and researchers with backgrounds in oncology, integrative medicine, metabolic medicine, and evidence-based clinical writing.
| Platform | Specialty |
|---|---|
| SmartCancer.org | Systems oncology intelligence, metabolic cancer, repurposed drugs, immunotherapy-metabolism |
| cancer.aestheticsadvisor.com | Integrative oncology hub for Southeast Asia — fenbendazole, ivermectin, CARE protocols |
| OneDayMD.com | Longevity, metabolic medicine, therapeutic peptides, supplement science |
| Find Oncologists Directory | Integrative oncology practitioner directory |
Who This Platform Serves
|
Cancer Patients
Seeking independent analysis beyond headlines, social media, and ungraded claims. You want models, not miracles.
|
❤
Caregivers & Families
Who need to understand complex treatment tradeoffs, ask better questions, and evaluate information rigorously on behalf of someone they love.
|
Integrative Clinicians
Seeking structured evidence synthesis on metabolic protocols, repurposed drugs, and systems oncology frameworks for patient counseling.
|
Researchers
Interested in metabolic oncology modeling, repurposed drug evidence synthesis, and case series analysis with CEBM evidence-tier framing.
|
Our Core Principle
Tumors adapt. Metabolism adapts. Immunity adapts. Our analysis adapts with them. The future of oncology is systems-based — and SmartCancer.org is built to map that complexity as it evolves.
AI Personalization Guide
How to use SmartCancer.org content with Claude, ChatGPT, Gemini, and Perplexity for best results.
SmartCancer.org content is structured for AI-assisted research. Use these prompt frameworks when querying AI assistants about topics covered on this platform:
Featured Resources & Key Articles
SmartCancer.org readers seeking physician-formulated supplement protocols may explore The Wellness Company (TWC) — use code ONEDAYMD at checkout. All affiliate relationships are disclosed and do not influence editorial content.
Frequently Asked Questions
About SmartCancer.org, the Cancer Companion Guide, and our evidence methodology.
Contact & Editorial Inquiries
|
Editorial & Collaboration
For editorial inquiries, factual corrections, or collaboration proposals — including research partnerships, clinical case contributions, and content review requests: |
Related Network Sites
|
The content published on SmartCancer.org is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. All information is provided as general educational material about metabolic oncology research and should not be used as a substitute for professional medical advice from a qualified oncologist or healthcare provider. Individual cancer cases vary significantly — always discuss any therapeutic strategy with your treating oncologist before implementation. SmartCancer.org is not responsible for clinical decisions made on the basis of information published on this platform. Evidence tiers reflect the best available published literature at the time of writing; the evidence base for repurposed drugs is evolving rapidly.
.jpeg)
Comments
Post a Comment